Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)

被引：0

作者：

Piekarz, Richard ^{[1
]}

Wright, John ^{[2
]}

Frye, Robin ^{[1
]}

Allen, Steven L. ^{[3
]}

Craig, Michael ^{[4
]}

Geskin, Larisa ^{[5
]}

Hutchins, Laura ^{[6
]}

Joske, David ^{[7
]}

Kirschbaum, Mark ^{[8
]}

Leonard, John P. ^{[9
]}

Prince, Miles ^{[10
]}

Reeder, Craig B. ^{[11
]}

Jaffe, Elaine ^{[1
]}

Bates, Susan ^{[12
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

[2] IDB CTEP NCI, Rockville, MD USA

[3] N Shore Univ, Hosp LIJ, Lake Success, NY USA

[4] Mary Babb Randolph Canc Ctr, Morgantown, WV USA

[5] Univ Pittsburgh, Pittsburgh, PA USA

[6] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

[7] Sir Charles Gairdner Hosp, Haematol Care Ctr, Perth, WA, Australia

[8] City Hope Natl Med Ctr, Div Hematol, Duarte, CA 91010 USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Peter MacCallum Canc Inst, Melbourne, Australia

[11] Mayo Clin Arizona, Scottsdale, AZ USA

[12] NCI, Bethesda, MD 20892 USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：555 / 556

页数：2

共 50 条

[21] A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study
Dupuis, Jehan
Casasnovas, Rene-Olivier
Ghesquieres, Herve
Morschhauser, Franck
Tilly, Herve
Thieblemont, Catherine
Ribrag, Vincent
Coiffier, Bertrand
BLOOD, 2012, 120 (21)
[22] Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
Kim, Won-Seog
Fukuhara, Noriko
Yoon, Dok-Hyun
Yamamoto, Kazuhito
Uchida, Toshiki
Negoro, Eiju
Izutsu, Koji
Terui, Yasuhito
Nakajima, Hideaki
Ando, Kiyoshi
Suehiro, Youko
Kang, Hye Jin
Ko, Po-Shen
Nagahama, Fumiko
Sonehara, Yusuke
Nagai, Hirokazu
Tien, Hwei-Fang
Kwong, Yok-Lam
Tobinai, Kensei
BLOOD ADVANCES, 2023, 7 (17) : 4903 - 4912
[23] A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)
Goh, Yeow-Tee
Hwang, William Y. K.
Diong, Colin Phipps
Hsien, Yap Chun
Tay, Kevin
Lim, Soon Thye
Lee, Yuh Shan
Ng, Soo Chin
Fadilah, S.
Kim, Won Seog
Tan, Daryl
BLOOD, 2014, 124 (21)
[24] A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
Strati, Paolo
Chihara, Dai
Oki, Yasuhiro
Fayad, Luis E.
Fowler, Nathan
Nastoupil, Loretta
Romaguera, Jorge E.
Samaniego, Felipe
Garg, Naveen
Feng, Lei
Wesson, Emily T.
Ruben, Charnelle E.
Stafford, Mildred D.
Nieto, Yago
Khouri, Issa F.
Hosing, Chitra
Horowitz, Sandra B.
T-Kamble, Rammurti
Fanale, Michelle A.
HAEMATOLOGICA, 2018, 103 (09) : E416 - E418
[25] Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Foss, Francine
Pro, Barbara
Miles Prince, H.
Sokol, Lubomir
Caballero, Dolores
Horwitz, Steven
Coiffier, Bertrand
CANCER MEDICINE, 2017, 6 (01): : 36 - 44
[26] Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials
Shustov, Andrei R.
Coiffier, Bertrand
Horwitz, Steven M.
Sokol, Lubomir
Pro, Barbara
Nielsen, Tina
Wolfson, Julie
Balser, Barbara E.
Eisch, Robin
Popplewell, Leslie
Prince, Miles
Allen, Steven L.
Piekarz, Richard
Bates, Susan E.
BLOOD, 2013, 122 (21)
[27] Romidepsin Is Effective and Well-Tolerated in Patients >= 60 Years Old With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (02) : 17 - 18
[28] Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
Dai Maruyama
Kunihiro Tsukasaki
Toshiki Uchida
Yoshinobu Maeda
Hirohiko Shibayama
Hirokazu Nagai
Mitsutoshi Kurosawa
Yoko Suehiro
Kiyohiko Hatake
Kiyoshi Ando
Isao Yoshida
Michihiro Hidaka
Tohru Murayama
Yoko Okitsu
Norifumi Tsukamoto
Masafumi Taniwaki
Junji Suzumiya
Kazuo Tamura
Takahiro Yamauchi
Ryuzo Ueda
Kensei Tobinai
Annals of Hematology, 2019, 98 : 131 - 142
[29] Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Foss F.
Coiffier B.
Horwitz S.
Pro B.
Prince H.M.
Sokol L.
Greenwood M.
Lerner A.
Caballero D.
Baran E.
Kim E.
Nichols J.
Balser B.
Wolfson J.
Whittaker S.
Biomarker Research, 2 (1)
[30] Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
Maruyama, Dai
Tsukasaki, Kunihiro
Uchida, Toshiki
Maeda, Yoshinobu
Shibayama, Hirohiko
Nagai, Hirokazu
Kurosawa, Mitsutoshi
Suehiro, Yoko
Hatake, Kiyohiko
Ando, Kiyoshi
Yoshida, Isao
Hidaka, Michihiro
Murayama, Tohru
Okitsu, Yoko
Tsukamoto, Norifumi
Taniwaki, Masafumi
Suzumiya, Junji
Tamura, Kazuo
Yamauchi, Takahiro
Ueda, Ryuzo
Tobinai, Kensei
ANNALS OF HEMATOLOGY, 2019, 98 (01) : 131 - 142

← 1 2 3 4 5 →